Glycan-functionalized lipid nanoparticles (LNPs) are lipid-based nanocarriers whose surfaces are decorated with carbohydrate ligands, from monosaccharides such as GalNAc, galactose, and mannose to polymeric glycans such as hyaluronic acid. These sugars act as recognition motifs for lectin receptors on defined cell populations, converting a standard LNP from a passive carrier into a receptor-directed delivery vehicle while preserving the core's capacity to encapsulate nucleic acids, small molecules, and proteins.
Most glycan-functionalized LNPs are built by conjugating the sugar to a lipid anchor, typically a phospholipid, a diacylglycerol, cholesterol, or a PEG-ceramide, and incorporating this glyco-lipid conjugate during assembly or after particle formation. The ligand determines which receptor is engaged and therefore which cell type is targeted: GalNAc and galactose bind the asialoglycoprotein receptor (ASGPR) on hepatocytes, mannose engages C-type lectin receptors on macrophages and dendritic cells, and hyaluronic acid interacts with CD44 on tumor and stromal cells. This ligand-to-receptor-to-cell logic makes glycan display one of the most practical surface-engineering strategies for cell-selective LNP delivery.
Selecting the right glycan is a formulation decision with direct consequences for biodistribution, cellular uptake, and payload activity, and it should be made together with decisions on ligand density, spacer length, and PEG content. The table below summarizes the major glycan classes. BOC Sciences supports the full development cycle through carbohydrate-conjugated lipid nanoparticle development, from glyco-lipid building block design and surface functionalization to formulation, characterization, and delivery evaluation, as part of its broader targeted LNP development platform.
Table 1. Classification of Glycan-Functionalized LNPs by Ligand, Receptor, and Target Cell.
| Glycan Ligand | Main Receptor | Primary Target Cells | Typical Delivery Applications |
| GalNAc | ASGPR | Hepatocytes | Hepatocyte-selective siRNA, mRNA, and gene-editing payload delivery |
| Galactose / lactose | ASGPR (lower monovalent affinity) | Hepatocytes | Liver-directed nucleic acid and small molecule delivery with simplified ligand chemistry |
| Mannose | CD206, MGL, DEC-205 | Macrophages, dendritic cells, Kupffer cells | Immune-cell targeting, vaccine antigen delivery, tumor-associated macrophage modulation |
| Hyaluronic acid | CD44, RHAMM | CD44-positive tumor cells, activated hepatic stellate cells | Tumor and fibrosis-associated delivery of nucleic acids and chemotherapeutics |
| Fucose, glucose, and other glycans | Fucose receptors, GLUT and other transporters | Kupffer cells, mesangial and epithelial cells | Emerging organ- and cell-selective applications under active investigation |
GalNAc-functionalized LNPs carry N-acetylgalactosamine ligands presented either as monovalent GalNAc-PEG-lipids or as triantennary clusters mounting three GalNAc residues on a branched scaffold. The ligand is recognized by the asialoglycoprotein receptor, a lectin highly and almost exclusively expressed on hepatocytes, which binds and internalizes particles displaying terminal GalNAc or galactose residues. Triantennary presentation raises binding affinity from the millimolar range typical of a single GalNAc residue into the nanomolar range, which is why multivalent GalNAc clusters are the preferred ligand architecture for hepatocyte-directed LNP work.
Optimizing an LNP into a GalNAc-LNP is appropriate in several situations. First, conventional ionizable LNPs reach the liver but depend on apolipoprotein E adsorption and low-density lipoprotein receptor-mediated uptake, pathways whose efficiency varies with lipid composition and biological system. GalNAc display provides a receptor-defined entry route into hepatocytes that can be manipulated and verified independently of ApoE-driven uptake. Second, when the payload must act in hepatocytes rather than in liver non-parenchymal cells, GalNAc targeting shifts uptake toward the parenchymal compartment. Third, when the goal is hepatocyte-selective silencing, expression, or editing with siRNA, mRNA, or gene-editing cargos, pairing the particle with a proven receptor ligand simplifies interpretation of delivery data. BOC Sciences develops GalNAc-conjugated lipid nanoparticles as part of its liver-targeted LNP development services, covering ligand design, conjugate synthesis, and formulation optimization.
Preparation proceeds in two stages: synthesis of the GalNAc-lipid conjugate and incorporation of the conjugate into the particle. In the first stage, GalNAc is coupled to a lipid anchor through a hydrophilic spacer, using anchors such as DSPE, distearoylglycerol, and cholesterol derivatives connected through PEG spacers that lift the ligand above the particle surface. Triantennary ligands typically use a lysine or triazine-based core bearing three GalNAc residues, conjugated to the lipid anchor by amide coupling or by copper-catalyzed azide-alkyne cycloaddition between an azide-functionalized GalNAc cluster and an alkyne-bearing lipid. Monovalent GalNAc-PEG-phospholipids are simpler to manufacture, at the cost of lower receptor affinity.
In the second stage, the purified conjugate is introduced into the LNP. Two incorporation modes are used:
Typical conjugate inputs fall in the range of 0.5 to 2 mol% of total lipid for triantennary ligands, with higher inputs evaluated carefully because excess glyco-lipid can alter particle assembly and increase aggregation tendency.
The GalNAc-lipid conjugate should be purified and verified before formulation. Flash chromatography, preparative HPLC, or size-exclusion chromatography removes unreacted sugars, coupling reagents, and incomplete conjugates, and the product is confirmed by mass spectrometry and nuclear magnetic resonance, with attention to the degree of GalNAc substitution.
After particle formation, purification by dialysis, tangential flow filtration, or size-exclusion chromatography removes ethanol, unencapsulated payload, and non-inserted conjugate. Physicochemical characterization then establishes whether ligand incorporation preserved particle quality, covering hydrodynamic diameter and polydispersity by dynamic light scattering, zeta potential, payload encapsulation efficiency, and morphology by cryo-TEM. Ligand-specific characterization closes the loop:
Intravenous administration is the primary route for GalNAc-functionalized LNPs, because it exposes the particles to the hepatic sinusoids where ASGPR-mediated capture occurs. Ionizable lipid choice sets the endosomal escape capacity of the particle, and its pKa window determines how much of the delivery benefit comes from the ligand rather than the core. PEG-lipid content and the PEG-lipid used for the GalNAc anchor jointly control ligand exposure, since a dense PEG layer can bury GalNAc head groups and abolish binding. Dosing strategy also matters: ASGPR is saturable, so ligand density and administered dose should be matched to keep the receptor pathway available rather than overwhelming it.
GalNAc targeting has been applied across payload classes relevant to liver research programs. For RNA interference work, GalNAc-LNPs carrying siRNA enable hepatocyte-selective knockdown of endogenous liver transcripts. For expression applications, GalNAc-LNPs carrying mRNA support hepatocyte-restricted protein production, and combination mRNA payloads have been explored in liver injury models. Gene-editing cargos, including Cas9 mRNA with guide RNA, have achieved editing levels in hepatocytes above those of non-targeted particles in the same core formulation.
Verification should demonstrate three things: the particle reached the liver, it entered hepatocytes preferentially, and the payload produced its intended effect through the targeted pathway. Whole-body and organ-level imaging of labeled particles establishes hepatic accumulation. Cell-level resolution comes from flow cytometry or microscopy of isolated liver cell fractions, comparing uptake in hepatocytes against Kupffer cells and liver sinusoidal endothelial cells, which distinguishes true parenchymal targeting from general liver deposition.
The summary table below consolidates the development workflow for this class.
Table 2. Development and Evaluation Workflow for GalNAc-Functionalized LNPs.
| Development Stage | Representative Methods and Readouts |
| Synthesis and Preparation | Solution-phase or click-chemistry synthesis of mono- and triantennary GalNAc-PEG-lipids; pre-assembly incorporation or post-insertion into ionizable LNPs; evaluate conjugate purity, substitution degree, particle size, PDI, and encapsulation efficiency. |
| In Vitro Verification | DLS, zeta potential, cryo-TEM, ligand quantification, ASGPR binding assays, uptake in ASGPR-positive versus ASGPR-negative cells, and competition with free GalNAc or asialofetuin to confirm receptor-dependent uptake. |
| Delivery Route | Intravenous administration as the primary route; ligand density and dose adjusted to ASGPR capacity; co-optimization with ionizable lipid pKa and PEG coverage. |
| In Vivo Delivery Verification | Whole-body imaging, hepatocyte versus non-parenchymal cell fraction analysis by flow cytometry or microscopy, reporter expression or gene-silencing readouts, and receptor-blockade controls demonstrating ASGPR-mediated delivery. |
BOC Sciences provides GalNAc-PEG-lipid building blocks, triantennary ligand synthesis, LNP formulation and post-insertion optimization, and full physicochemical and biological characterization for hepatocyte-targeted nanoparticle programs.
Galactose-functionalized LNPs display terminal galactose or lactose residues on the particle surface and target the same receptor system as GalNAc particles: ASGPR on hepatocytes recognizes desialylated glycoproteins bearing exposed galactose or GalNAc termini. The distinction is affinity and architecture. A single galactose residue binds ASGPR with millimolar affinity, far weaker than a triantennary GalNAc cluster, so galactose-based particles rely on multivalent display, high ligand density, and adequate spacer length to achieve productive receptor engagement. Lactose, presented through lactobionic acid, is the most frequently used galactose-derived ligand in lipid nanocarrier work.
Choosing galactose over GalNAc is reasonable in several scenarios. When the program needs a straightforward, well-characterized hepatocyte-targeting ligand and can tolerate higher ligand density, galactosylated lipids offer simpler synthesis and easier spacer modification. When the payload is a small molecule or imaging agent rather than a potent nucleic acid, the moderate affinity of galactose display is often sufficient. High ligand densities should be applied with care, since galactosylated particles pushed above roughly 5 mol% ligand content have been observed to shift from hepatocyte uptake toward non-parenchymal liver cells, reflecting receptor saturation and alternative lectin engagement. BOC Sciences supports this class through its galactose-conjugated lipid nanoparticle development services, including ligand density screening and head-group comparisons.
The most widely used conjugation route couples lactobionic acid, which carries a terminal galactose and a carboxyl handle, to amino-functionalized lipids such as DSPE-PEG-NH2 or cholesterol-based amino lipids. Amide bond formation is mediated by carbodiimide chemistry, typically EDC with NHS activation, in aqueous or mixed solvent systems. The PEG spacer between the lipid anchor and the galactose head group is a critical design variable: spacers that are too short leave the sugar buried against the particle surface and unable to reach the receptor binding pocket, whereas longer spacers improve accessibility but can reduce membrane retention at very high chain lengths.
Incorporation into particles follows the same two options described for GalNAc systems, either co-formulation during microfluidic assembly or post-insertion into preformed LNPs, with working ligand inputs usually between 1 and 5 mol%.
Conjugate purification uses chromatographic removal of unreacted sugar acids, coupling reagents, and partially substituted products, with structural confirmation by mass spectrometry and NMR. At the particle level, dialysis or tangential flow filtration removes residual solvent and free conjugate, and standard quality attributes, including size, polydispersity, zeta potential, and encapsulation efficiency, are benchmarked against the unmodified parent formulation so that ligand-induced degradation is detected early.
Because galactose display depends on density and accessibility rather than high intrinsic affinity, ligand-focused characterization deserves particular attention. Galactose content on purified particles can be quantified by carbohydrate assays or by HPLC with conjugate-specific detection. Receptor engagement is tested in hepatocyte uptake assays with and without competitive inhibitors such as asialofetuin or free galactose, and binding to isolated ASGPR provides a direct affinity measurement. Comparing particles that differ only in spacer length or ligand density identifies the presentation geometry that maximizes receptor binding without compromising colloidal stability.
As with GalNAc particles, intravenous injection is the dominant delivery route, placing the particles in direct contact with the hepatic sinusoidal vasculature. The main strategic difference is ligand dosage rather than route: because monovalent galactose binds weakly, productive targeting requires enough surface ligand for multivalent receptor engagement, but excessive density saturates ASGPR and opens alternative uptake pathways in non-parenchymal cells. Spacer chemistry and PEG architecture must therefore be balanced against this density requirement. Galactose-functionalized systems have been applied to hepatocyte-directed delivery of chemotherapeutics, anti-fibrotic agents, and nucleic acids in research settings, and they serve as accessible models for studying ligand-mediated versus ApoE-mediated hepatic uptake.
Verification mirrors the GalNAc workflow with an added emphasis on receptor saturation. Whole-body imaging and organ biodistribution confirm hepatic delivery, while cell-fraction analysis distinguishes hepatocyte uptake from capture by Kupffer cells and sinusoidal endothelium. Functional readouts, such as reporter expression for mRNA payloads or target knockdown for siRNA payloads, quantify delivery efficiency in liver tissue.
Table 3. Development and Evaluation Workflow for Galactose-Functionalized LNPs.
| Development Stage | Representative Methods and Readouts |
| Synthesis and Preparation | Lactobionic acid coupling to amino-PEG-lipids by EDC/NHS chemistry, reductive amination, thiol-maleimide or click ligation; co-formulation or post-insertion at 1 to 5 mol% ligand input; evaluate substitution degree, spacer-dependent binding, and particle quality. |
| In Vitro Verification | Carbohydrate quantification on particles, ASGPR binding and surface plasmon resonance, hepatocyte uptake in ASGPR-positive versus negative cells, and competition with asialofetuin or free galactose. |
| Delivery Route | Intravenous administration with ligand density tuned below the receptor saturation threshold; spacer length and PEG coverage co-optimized for ligand accessibility. |
| In Vivo Delivery Verification | Hepatic biodistribution imaging, hepatocyte versus non-parenchymal fraction analysis, functional expression or silencing readouts, and ligand-density-dependent targeting comparisons. |
BOC Sciences offers galactose and lactose lipid conjugates, ligand density and spacer screening, formulation development, and comparative uptake studies to establish receptor-mediated hepatocyte targeting.
Mannose-functionalized LNPs present mannose residues that are recognized by C-type lectin receptors, principally the macrophage mannose receptor CD206, together with related receptors such as MGL and DEC-205. These receptors are expressed on macrophage lineages, including Kupffer cells and tumor-associated macrophages, and on dendritic cells, making mannose the principal glycan ligand for redirecting LNPs from hepatocytes toward immune cell populations. In liver applications, mannosylated particles shift uptake from parenchymal cells to Kupffer cells, a property exploited for anti-inflammatory and immune-modulation studies. In oncology and immunology programs, mannose display targets payloads to tumor-associated macrophages for repolarization studies and to dendritic cells for antigen delivery.
Optimizing an LNP into a mannose-LNP is appropriate when the intended target cells are myeloid or antigen-presenting populations: macrophage-selective siRNA delivery, dendritic-cell-directed vaccine antigen delivery, and modulation of tumor-associated macrophage phenotypes are the leading use cases, and it is also the natural choice when hepatocyte uptake must be avoided rather than enhanced. Because mannose receptors, like ASGPR, are saturable and receptor density varies between cell types, program design should account for ligand multivalency requirements, since productive CD206 engagement generally requires dense, well-spaced mannose display rather than sparse decoration. BOC Sciences develops mannose-conjugated lipid nanoparticles for immune-cell targeting programs, including work connected to its lipid nanoparticle for vaccine development and spleen-targeted LNP development services.
Mannose lacks a convenient carboxyl handle, so conjugation chemistries differ from the galactose systems. The classic route uses reductive amination: the open-chain aldehyde form of mannose reacts with an amino-functionalized lipid, such as DSPE-PEG-NH2, and the resulting imine is reduced to a stable secondary amine. This chemistry is robust and compatible with scale-up, though it consumes the anomeric carbon of the sugar, which is acceptable for CD206 recognition.
Incorporation strategies again divide into pre-assembly formulation and post-insertion. For dendritic-cell and lymph node applications, where particles are delivered by routes other than the intravenous one, post-insertion into a finished vaccine formulation allows the same core particle to be adapted to different targeting requirements.
Purification of mannosylated conjugates follows standard chromatographic removal of unreacted sugar derivatives and coupling byproducts, with structural verification by mass spectrometry and NMR. Particles are cleaned up by dialysis, ultrafiltration, or size-exclusion chromatography and profiled for size, polydispersity, zeta potential, encapsulation efficiency, and morphology, with the unmodified parent formulation as the benchmark.
Ligand-focused characterization centers on lectin recognition. Mannose content on particles can be quantified by carbohydrate assays or by lectin-based detection using mannose-binding lectins such as concanavalin A as an analytical probe. Receptor-level characterization uses CD206-expressing macrophage and dendritic cell models, with uptake measured by flow cytometry and confocal microscopy. Mannan, a high-molecular-weight mannose polymer, serves as a convenient competitive inhibitor: a clear reduction of uptake in the presence of mannan, and in CD206-blocked conditions, establishes that internalization is receptor-mediated. Because myeloid cells are also highly phagocytic, serum conditions and proper size matching to non-mannosylated controls are important so that receptor-mediated uptake is not confused with nonspecific phagocytosis.
Delivery routes for mannose-LNPs are more varied than for the hepatocyte-targeted classes because the target populations reside in different compartments. For liver macrophages, Kupffer cells, and tumor-associated macrophages, intravenous administration is used, with particle size and ligand density controlling the balance between Kupffer-cell capture and access to tumor-resident myeloid cells. For dendritic-cell targeting in immunization studies, subcutaneous and intramuscular routes drain to lymph nodes rich in CD206-positive antigen-presenting cells, and mannose display improves uptake in these draining populations. Pulmonary and intranasal routes direct particles toward alveolar macrophages. Across all routes, the ionizable and helper lipid composition determines whether receptor-mediated uptake converts into functional payload delivery; endosomal escape capacity often limits the activity of mannose-targeted nucleic acid particles more than receptor binding itself.
Verification must connect particle localization to specific immune cell populations and then to functional payload activity. Imaging establishes organ-level distribution, while flow cytometry of tissue-derived immune fractions, using markers that separate macrophages, dendritic cells, and other myeloid subsets, provides cell-resolved uptake data that imaging alone cannot deliver.
Table 4. Development and Evaluation Workflow for Mannose-Functionalized LNPs.
| Development Stage | Representative Methods and Readouts |
| Synthesis and Preparation | Reductive amination, isothiocyanate coupling, or click ligation of mannose derivatives to PEG-lipids; multivalent mannose cluster construction; co-formulation or post-insertion into macrophage- or DC-directed LNP cores. |
| In Vitro Verification | Mannose quantification, lectin-binding probes, uptake in CD206-positive macrophage and dendritic cell models versus negative controls, and competition with mannan to confirm receptor-mediated internalization. |
| Delivery Route | Intravenous for liver and tumor myeloid cells; subcutaneous or intramuscular for lymph node dendritic cells; pulmonary or intranasal for alveolar macrophages. |
| In Vivo Delivery Verification | Immune-fraction flow cytometry, imaging-based biodistribution, receptor-blockade controls, and functional readouts including antigen presentation, T-cell activation, and macrophage transcript knockdown. |
BOC Sciences supplies mannosylated lipid conjugates, multivalent ligand design, immune-cell uptake evaluation, and route-specific formulation support for macrophage- and dendritic-cell-targeted nanoparticle programs.
Hyaluronic acid-functionalized LNPs carry surface-displayed HA, a linear glycosaminoglycan of repeating glucuronic acid and N-acetylglucosamine units, and target cells expressing CD44, its principal receptor, along with the related receptor RHAMM. CD44 is upregulated across a broad set of tumor types, on activated hepatic stellate cells in fibrotic liver, and on selected myeloid and endothelial populations, giving HA display a targeting range that extends beyond the liver-centered applications of GalNAc and galactose systems. Unlike monosaccharide ligands, HA is a polymer, so its molecular weight is itself a design variable that shapes receptor engagement, circulation behavior, and clearance.
Optimizing an LNP into an HA-LNP is indicated when the target population is CD44-positive: delivery of nucleic acids or cytotoxic payloads to tumor cells and tumor-associated stroma, targeting of activated stellate cells in hepatic fibrosis models, and CD44-directed uptake where the tumor microenvironment limits passive accumulation. Molecular weight selection should match the application. High-molecular-weight HA supports multivalent CD44 engagement but can accelerate liver uptake and clearance through HA-handling pathways, while short HA oligosaccharides may reduce hepatic sequestration at the cost of weaker receptor engagement. BOC Sciences supports this class through its hyaluronic acid-conjugated lipid nanoparticle development services, which connect HA conjugate design with tumor-targeted LNP development programs.
The dominant preparation route synthesizes an HA-lipid conjugate and incorporates it into the particle. Carboxyl groups along the HA backbone are activated with EDC/NHS chemistry and coupled to amino-functionalized lipids such as DPPE or DSPE-PEG-NH2, producing amide-linked conjugates in which the lipid anchor embeds in the particle shell and the HA chain projects into the aqueous phase. Cholesterol-linked HA conjugates are also used, taking advantage of cholesterol's affinity for the LNP core. The degree of substitution, the HA molecular weight, and the conjugate mol% jointly determine surface density and chain extension.
A second, operationally simpler route is electrostatic coating. Cationic or freshly prepared ionizable LNPs present a positively charged surface to which anionic HA adsorbs spontaneously, forming a shell without covalent chemistry. The coating is less stable than covalent conjugates, and final surface charge must be verified to ensure particles are not strongly cationic after coating. A third route, post-assembly covalent coupling, attaches HA directly to reactive groups incorporated into a preformed particle surface, which suits programs that must retarget an already optimized, payload-loaded formulation.
HA-lipid conjugates are purified by dialysis or ultrafiltration, with the membrane molecular weight cutoff chosen against the HA chain length, and characterized by NMR and infrared spectroscopy to confirm lipid attachment and estimate substitution degree. Coated particles are purified to remove free HA, which otherwise competes for receptor binding in downstream assays, and profiled for size, polydispersity, zeta potential, and encapsulation efficiency.
Intravenous administration is the main route for tumor and hepatic stellate cell targeting, where HA display is expected to add receptor-mediated capture on top of passive accumulation in well-perfused tissues. Particle design must anticipate the biology of HA handling: circulating HA-binding proteins and liver HA receptors take up HA-displaying particles, and long HA chains in particular can shift distribution toward hepatic and lymphatic clearance. Local and regional routes, including intratumoral administration in research settings, bypass circulation-related losses and test the receptor-targeting mechanism directly. Across routes, the balance between HA molecular weight, surface density, and PEG content on the underlying particle determines whether CD44 engagement or HA-mediated clearance dominates, and this balance is the central optimization axis of the class.
Verification should establish that HA display produced CD44-dependent delivery rather than a general redistribution of the particle. Whole-body imaging quantifies accumulation in target tissue against major off-target organs, and tissue-level analysis by flow cytometry and microscopy resolves which cell populations within the target tissue took up the particles.
Table 5. Development and Evaluation Workflow for Hyaluronic Acid-Functionalized LNPs.
| Development Stage | Representative Methods and Readouts |
| Synthesis and Preparation | EDC/NHS coupling of HA to DPPE or PEG-lipids across defined molecular weights; electrostatic coating of cationic or ionizable LNPs; post-assembly covalent coupling; evaluate substitution degree, coating stability, and particle quality. |
| In Vitro Verification | Surface HA quantification, charge verification by zeta potential, CD44-positive versus CD44-negative uptake comparison, and free HA competition binding studies. |
| Delivery Route | Intravenous for tumor and hepatic stellate cell targeting; local and intratumoral routes for direct receptor-mechanism evaluation; HA molecular weight balanced against hepatic clearance behavior. |
| In Vivo Delivery Verification | Whole-body imaging, CD44-resolved tissue flow cytometry and microscopy, receptor-blockade controls, and functional expression or silencing readouts in target tissue. |
BOC Sciences provides HA materials across defined molecular weights, HA-lipid conjugate synthesis, coating and conjugation development, and CD44-focused cellular and in vivo evaluation for tumor and fibrosis targeting programs.
The most frequent cause of a non-functional glycan-LNP is not the absence of the ligand but its inaccessibility. GalNAc, galactose, and mannose head groups attached through short spacers can sit within or behind the PEG corona of the particle, unable to bridge the distance to the receptor binding pocket, and uptake then reverts to the untargeted behavior of the core formulation. Diagnosis relies on comparing ligand quantification with functional binding: a particle with ample incorporated glyco-lipid but weak lectin binding almost certainly has a presentation problem rather than a composition problem.
Optimization operates on spacer length, anchor architecture, and ligand density. Extending the spacer, typically by moving to longer PEG spacers between the lipid anchor and the sugar, restores receptor reach. Increasing glyco-lipid mol% raises the probability of multivalent engagement but must be balanced against the assembly effects discussed below; a useful approach is to screen a small ligand density matrix rather than a single working point. BOC Sciences addresses these issues through its LNP PEG-lipid optimization services, which pair spacer design with binding verification.
Glyco-lipids are not passive additives. At high mol%, bulky head groups and altered packing geometry can disrupt particle assembly during microfluidic mixing, producing larger diameters, broader polydispersity, lower encapsulation efficiency, and sometimes visible aggregation. Polymeric ligands such as HA amplify the effect because a single conjugate contributes substantial hydrodynamic volume and anionic charge. A common failure pattern is a formulation that shows improved receptor binding but has silently lost 20 percentage points of encapsulation or drifted in size, so the net delivery gain is negative.
A glycan ligand only steers particles that reach the target cell, and in biological fluids the surface that target cells see is a protein corona, not the synthetic surface. Adsorbed proteins can bury glycan head groups, blunt lectin binding, and re-route particles through protein-mediated uptake. In hepatic targeting this is particularly consequential: conventional ionizable LNPs are taken up by hepatocytes efficiently through ApoE- and LDLR-mediated pathways, and unless ligand engagement is strong, the measured liver uptake of a GalNAc or galactose particle may simply reflect the core formulation rather than the ligand. Programs that evaluate targeting only in serum-free conditions routinely overestimate ligand contribution.
Two practices separate genuine receptor targeting from protein-driven uptake. First, uptake assays should be run in serum-containing conditions, with receptor-blockade and free-sugar competition controls, so the ligand contribution is measured under realistic protein exposure. Second, core-matched comparisons against non-targeted particles quantify the incremental effect of the ligand; if a GalNAc particle barely outperforms its untargeted twin, the formulation needs stronger ligand presentation or a core whose ApoE-dependence is reduced. Where receptor engagement must be demonstrated unambiguously, pathway controls such as LDLR-perturbed comparison conditions help attribute uptake to ASGPR rather than to background hepatic mechanisms.
Even correctly displayed ligands can steer particles to the wrong destination. Mannose display deliberately attracts macrophage uptake, but the same property draws particles into Kupffer cells when the intended target is a tumor-associated macrophage population, and into splenic red pulp in spleen-rich models. HA display interacts with liver HA-handling pathways, and high-molecular-weight HA coatings can accelerate hepatic sequestration rather than tumor delivery. Independent of ligand, repeated dosing of PEG-containing particles can induce accelerated blood clearance through anti-PEG immune mechanisms, and oversized or cationic particles are cleared by the mononuclear phagocyte system regardless of ligand identity.
Optimization is compartment-specific. For macrophage-rich off-target compartments, particle size below the threshold favored by phagocytic capture, careful ligand density titration, and route selection change the balance between target and reservoir uptake. For HA systems, molecular weight and coating density are the primary levers, with shorter HA chains and lower surface density reducing hepatic sequestration. Where repeated dosing degrades performance, dose spacing, PEG-lipid redesign, and zeta potential optimization that removes residual cationic charge reduce nonspecific capture. BOC Sciences supports systematic resolution of these failure modes through its LNP transfection troubleshooting services and LNP encapsulation efficiency optimization programs.
Table 6. Common Failure Modes in Glycan-Functionalized LNP Delivery and Optimization Directions.
| Observed Problem | Probable Root Cause | Optimization Direction |
| Ligand incorporated but receptor binding is weak | Head groups buried in the PEG corona; spacer too short; ligand density too low for multivalent engagement | Extend spacer length, reduce competing PEG content, screen a ligand density matrix, and confirm binding with lectin assays |
| Size, PDI, or encapsulation worsen after glyco-lipid addition | Glyco-lipid mol% exceeds the assembly tolerance of the core; polymeric ligand adds excess volume and charge | Lower ligand input, retune helper lipid and cholesterol ratios, or move ligand addition to post-insertion |
| Targeting advantage disappears in serum or in vivo | Protein corona masks glycans; ApoE-driven uptake dominates; assays run without serum overestimate ligand effects | Evaluate in serum conditions, add receptor-blockade and core-matched controls, strengthen ligand presentation or adjust core ApoE-dependence |
| Particles accumulate in liver macrophages or spleen instead of target cells | Ligand-driven or size-driven phagocytic capture; HA molecular weight engaging hepatic clearance pathways | Reduce particle size and residual cationic charge, titrate ligand density, select shorter HA chains, adjust dose spacing |
BOC Sciences' experienced formulation scientists diagnose low receptor binding, encapsulation loss, serum-driven uptake, and off-target distribution, and deliver practical optimization paths for glycan-functionalized LNP programs.
Ligand chemistry is the foundation of every glycan-LNP program, and BOC Sciences provides it through dedicated custom synthesis of glycan ligands and glyco-lipid building blocks. Capabilities cover monovalent and multivalent GalNAc clusters, galactose and lactose conjugates, mannosylated lipids produced by reductive amination or click chemistry, and HA-lipid conjugates across defined molecular weights, each mounted on selected anchors including DSPE, distearoylglycerol, cholesterol, and PEG-ceramide with customizable spacer lengths. Conjugates are purified and structurally confirmed before formulation, so downstream optimization starts from a chemically defined starting point.
BOC Sciences converts glyco-lipid building blocks into working particles through integrated nanoparticle surface functionalization services and lipid nanoparticle formulation development. Particles are assembled with pre-incorporated ligands by microfluidic LNP production, or ligands are introduced afterward by post-insertion or surface conjugation, depending on whether the core formulation is being built fresh or retargeted. Payload loading, including lipid nanoparticle encapsulation of nucleic acids, small molecules, and proteins, is optimized together with ligand density so that targeting gains are not traded away for loading losses.
Every formulation is supported by a complete analytical package through BOC Sciences' lipid nanoparticle characterization services: particle size and polydispersity by nanoparticle size analysis, surface charge by zeta potential analysis, and morphology by nanoparticle morphology characterization, complemented by encapsulation efficiency, ligand quantification, and stability profiling. Glycan-specific analytics, including carbohydrate content on purified particles and lectin-binding measurements, verify that the intended surface architecture was actually achieved.
Targeting claims are validated with receptor-resolved evidence. In vitro evaluation through nanoparticle cellular uptake testing compares receptor-positive and receptor-negative cell models, applies free-sugar and receptor-blockade competition controls, and links uptake to functional payload delivery, supported by endosomal escape evaluation for nucleic acid cargos. At the organism level, in vivo imaging services and in vivo distribution analysis quantify organ and cell-level biodistribution, delivering the comparative data needed to select the glycan, ligand density, and route for each program.
The table below summarizes the principal service modules for glycan-functionalized LNP programs.
Table 7. BOC Sciences Services for Glycan-Functionalized LNP Development.
| Service | Description | Inquiry |
| GalNAc-Conjugated Lipid Nanoparticle Development | Mono- and triantennary GalNAc ligand synthesis, incorporation, and ASGPR-targeted formulation development for hepatocyte-directed delivery. | Inquiry |
| Galactose-Conjugated Lipid Nanoparticle Development | Galactose and lactose lipid conjugates, ligand density and spacer screening, and hepatocyte-selective uptake verification. | Inquiry |
| Mannose-Conjugated Lipid Nanoparticle Development | Mannosylated lipid synthesis, multivalent display design, and macrophage- and dendritic-cell-targeted formulation development. | Inquiry |
| Hyaluronic Acid-Conjugated Lipid Nanoparticle Development | HA-lipid conjugates across defined molecular weights, coating and conjugation strategies, and CD44-directed delivery evaluation. | Inquiry |
| Glycan-Lipid Building Block Custom Synthesis | Custom glycan ligands, glyco-lipid conjugates, and spacer and anchor variants synthesized and structurally confirmed for formulation use. | Inquiry |
| Ligand Density and Presentation Optimization | Spacer length, ligand density, and PEG architecture screening with lectin-binding verification to maximize receptor accessibility. | Inquiry |
| Glycan-LNP Purification and Physicochemical Characterization | Size, PDI, zeta potential, morphology, encapsulation, ligand quantification, and stability analysis for glycan-functionalized particles. | Inquiry |
| Lectin Binding and Cellular Targeting Evaluation | Receptor-positive versus receptor-negative uptake studies, competition and blockade controls, and functional payload delivery assessment. | Inquiry |
| In Vivo Biodistribution and Delivery Verification | Whole-body imaging, organ and cell-level distribution analysis, and functional expression or silencing readouts in target tissues. | Inquiry |
Glycan-functionalized lipid nanoparticles convert a passive nanocarrier into a receptor-directed delivery platform by displaying carbohydrate ligands that engage defined lectin receptors: GalNAc and galactose drive ASGPR-mediated hepatocyte uptake, mannose redirects particles toward CD206-expressing macrophages and dendritic cells, and hyaluronic acid engages CD44 on tumor and activated stellate cell populations. Each class differs in ligand chemistry, affinity requirements, and target biology, yet all four depend on the same development logic: assembling an accessible, correctly density-tuned ligand display on a stable core, verifying receptor-dependent uptake under serum conditions with proper blockade controls, and confirming functional delivery at the cell and tissue level in in vivo studies. Where performance falls short, systematic diagnosis of ligand burial, assembly disruption, protein corona interference, and off-target clearance recovers targeting benefit without rebuilding the program. BOC Sciences supports this full workflow with glyco-lipid building block synthesis, glycan surface functionalization, LNP formulation and purification, physicochemical characterization, and cellular and in vivo delivery verification services for hepatocyte-, immune cell-, and tumor-targeted research programs.